{"id":401,"date":"2022-06-28T07:48:59","date_gmt":"2022-06-28T07:48:59","guid":{"rendered":"https:\/\/www.junshipharma.com\/rd-pipeline\/"},"modified":"2022-09-06T12:15:13","modified_gmt":"2022-09-06T12:15:13","slug":"rd-pipeline","status":"publish","type":"page","link":"https:\/\/www.junshipharma.com\/en\/rd-pipeline\/","title":{"rendered":"R&D Pipeline"},"content":{"rendered":"\n
Focusing on innovation<\/strong> and patient accessibility<\/strong>, we have established a diversified and complementary R&D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases.<\/p>\n\n As we continue to enrich our pipeline and explore combination treatments, our fields of innovation R&D has expanded from monoclonal antibodies to small molecule drugs, polypeptide drugs, antibody-drug conjugates (ADCs), bispecific antibody or multispecific antibody drugs, nucleotide drugs and etc. We will continue to further explore the next generation of innovative therapies for cancer and autoimmune diseases.<\/p>\n","protected":false},"excerpt":{"rendered":" Focusing on innovation and patient accessibility, we have established a diversified and complementary R&D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases. As we continue […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/pipeline.php","meta":{"footnotes":""},"class_list":["post-401","page","type-page","status-publish","hentry"],"yoast_head":"\n